% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Lanz:119439,
author = {T. Lanz$^*$ and S. K. Williams and A. Stojic and S.
Iwantscheff and J. Sonner$^*$ and C. Grabitz and S.
Becker$^*$ and L.-I. Böhler$^*$ and S. R. Mohapatra$^*$ and
F. Sahm$^*$ and G. Küblbeck$^*$ and T. Nakamura and H.
Funakoshi and C. Opitz$^*$ and W. Wick$^*$ and R. Diem$^*$
and M. Platten$^*$},
title = {{T}ryptophan-2,3-{D}ioxygenase ({TDO}) deficiency is
associated with subclinical neuroprotection in a mouse model
of multiple sclerosis.},
journal = {Scientific reports},
volume = {7},
issn = {2045-2322},
address = {London},
publisher = {Nature Publishing Group},
reportid = {DKFZ-2017-00181},
pages = {41271 -},
year = {2017},
abstract = {The catabolism of tryptophan to immunosuppressive and
neuroactive kynurenines is a key metabolic pathway
regulating immune responses and neurotoxicity. The
rate-limiting step is controlled by
indoleamine-2,3-dioxygenase (IDO) and
tryptophan-2,3-dioxygenase (TDO). IDO is expressed in
antigen presenting cells during immune reactions, hepatic
TDO regulates blood homeostasis of tryptophan and neuronal
TDO influences neurogenesis. While the role of IDO has been
described in multiple immunological settings, little is
known about TDO's effects on the immune system.
TDO-deficiency is neuroprotective in C. elegans and
Drosophila by increasing tryptophan and specific
kynurenines. Here we have determined the role of TDO in
autoimmunity and neurodegeneration in experimental
autoimmune encephalomyelitis (EAE), a model of multiple
sclerosis. We created reporter-TDO mice for in vivo imaging
to show that hepatic but not CNS TDO expression is activated
during EAE. TDO deficiency did not influence myelin-specific
T cells, leukocyte infiltration into the CNS, demyelination
and disease activity. TDO-deficiency protected from neuronal
loss in the spinal cord but not in the optic nerves. While
this protection did not translate to an improved overt
clinical outcome, our data suggest that spatially distinct
neuroprotection is conserved in mammals and support TDO as a
potential target for treatment of diseases associated with
neurodegeneration.},
cin = {G160 / L101 / G161 / G380 / D110 / G370},
ddc = {000},
cid = {I:(DE-He78)G160-20160331 / I:(DE-He78)L101-20160331 /
I:(DE-He78)G161-20160331 / I:(DE-He78)G380-20160331 /
I:(DE-He78)D110-20160331 / I:(DE-He78)G370-20160331},
pnm = {317 - Translational cancer research (POF3-317)},
pid = {G:(DE-HGF)POF3-317},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:28117398},
pmc = {pmc:PMC5259766},
doi = {10.1038/srep41271},
url = {https://inrepo02.dkfz.de/record/119439},
}